PCSK9 inhibitors

DocWire News EditorsCardiology | April 11, 2023
Adverse cardiovascular outcomes were more prevalent among patients with rejected or abandoned PCSK9 inhibitor ...
Read More
DocWire News EditorsLipid Management | May 2, 2023
A recent analysis of the results of the ODYSSEY OUTCOMES trail suggests that the PCSK9 inhibitor alirocumab added to ...
DocWire News EditorsCardiology | June 21, 2019
This week's edition features articles with expert commentary by Chris Cannon, MD, a cardiologist at Brigham and Women's ...
DocWire News EditorsAmerican Diabetes Association Scientific Sessions 2019 | April 11, 2023
A majority of patients with type 2 diabetes mellitus, atherosclerotic cardiovascular disease, and low density ...
DocWire News EditorsAtherosclerotic Disease | April 11, 2023
A new brief report in JAMA Cardiology suggests that the PCSK9 inhibitor evolocumab paired with adequate background ...
DocWire News EditorsLipid Management | May 2, 2023
Results from a recent cohort study suggest that evolocumab was associated with a 50% reduction in low-density ...
DocWire News EditorsCardiology | May 2, 2023
DocWire News talks with Chris Cannon, MD, cardiologist and professor of medicine at Harvard Medical School and a ...
Advertisement
Advertisement
Latest News

March 28, 2024